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Abstract  27 
Background: Escherichia coli bloodstream infections (EC-BSIs), particularly antibiotic-28 
resistant EC-BSIs, are increasing in the UK and internationally. The evidence base to guide 29 
interventions against this major public health concern is limited. We aimed to investigate 30 
possible drivers of changes in EC-BSI incidence and antibiotic susceptibilities in Oxfordshire 31 
over the last two decades, while stratifying for hospital-exposure. 32 
Methods: EC-BSIs and E. coli urinary tract infections (EC-UTIs) incidence in one UK region 33 
(Oxfordshire) were estimated from anonymised linked microbiological and hospital electronic 34 
health records, and modelled using negative binomial regression based on microbiological, 35 
clinical and healthcare exposure risk factors. Infection severity, 30-day all-cause mortality, 36 
and community and hospital co-amoxiclav use were also investigated. 37 
Findings: From 1998-2016, 5706 EC-BSIs occurred in 5215 patients, and 228376 EC-UTIs 38 
in 137075 patients. 1365(24%) EC-BSIs were nosocomial (onset >48h post-admission), 39 
1863(33%) were community (>365 days post-discharge), 1346(24%) quasi-community (31-40 
365 days post-discharge), and 1132(20%) quasi-nosocomial (≤30 days post-discharge). 41 
1413(20%) EC-BSIs and 36270(13%) EC-UTIs were co-amoxiclav-resistant (41% and 30%, 42 
respectively, in 2016). Increases in EC-BSIs were driven by increases in community 43 
(10%/year (95% CI:7%-13%)) and quasi-community (8%/year (95% CI:7%-10%)) cases. 44 
Changes over time in EC-BSI-associated 30-day mortality were at most modest in the 45 
nosocomial (rate ratio=0·98 (95% CI 0·96,1·00), p=0·03) and quasi-nosocomial (0·98 46 
(0·95,1·00), p=0·06) groups, with no evidence for changes in mortality in the quasi-47 
community (0·99 (0·96,1·01), p=0·32) and community (0·99 (0·96,1·01), p=0·21) groups. 48 
Mortality was, however, substantial (14-25% across groups). By contrast, co-amoxiclav-49 
resistant EC-BSIs increased in all groups (by 11%-19%/year, significantly faster than 50 
susceptible EC-BSIs, pheterogeneity<0·0001), as did co-amoxiclav-resistant EC-UTIs (by 13%-51 
29%/year, pheterogeneity<0·0001). Co-amoxiclav use in primary-care facilities was associated 52 
with subsequent co-amoxiclav-resistant EC-UTIs (p=0·03) and all EC-UTIs (p=0·002).  53 
3 
Interpretation: Current increases in EC-BSIs in Oxfordshire are primarily community-54 
associated, with high rates of co-amoxiclav resistance; nevertheless, there was little or no 55 
change in mortality. Focussing interventions on primary-care facilities, particularly with high 56 
co-amoxiclav usage may be most effective, in this region and more generally. 57 
Funding: National Institute for Health Research.  58 
4 
Research in context 59 
Evidence before this study 60 
We searched PubMed for publications from 1999-23 March 2018 , with the terms 61 
(“Escherichia coli” OR “E. coli”) AND (“bacteraemia” OR “bloodstream infection”), restricting 62 
the search to English language articles, and reviewed titles to identify relevant articles, and 63 
reference lists from relevant articles. Escherichia coli (E. coli) is one of the most common 64 
causes of bloodstream infection, and the incidence of E. coli bloodstream infection, and 65 
particularly antibiotic-resistant infections, is increasing in the UK and Europe.  Although a 66 
previous study found increases in E. coli bacteraemias in Oxfordshire, this was through 2011 67 
only and did not investigate drivers in detail.  The UK government aims to reduce healthcare-68 
associated E. coli bloodstream infection; however, there is only limited evidence to inform 69 
appropriate interventions in the current era. Factors that may have contributed to the 70 
increasing incidence include the aging population and the increase in antibiotic use and 71 
antibiotic-resistant isolates. The percentage of cases that were identified within two days of 72 
admission has increased marginally over time. Voluntarily reported data reveals little change 73 
in terms of the most likely primary focus over time, with urinary tract infection consistently 74 
being the most frequent primary focus for E. coli bacteraemia cases. Incidence generally 75 
increases with higher temperatures. 76 
 77 
Added value of this study 78 
We investigated potential drivers for these increases in incidence by exploiting available 79 
linked electronic health records over 19 years for ~5200 patients with E. coli bloodstream 80 
infection and ~140000 with E. coli urinary tract infection, together with community 81 
antimicrobial prescribing data for the most recent six years. Our study identified several 82 
findings with significant implications for health policy and patient care: 83 
 Increases in the incidence of E. coli bloodstream infections were driven mainly by 84 
non-hospital-associated cases; standardising for age and sex explained only 10-85 
5 
26%, and standardising additionally for blood cultures taken only 9-28%, of the 86 
increase with the smallest percentage explained in non-hospital-associated cases; 87 
increases did not appear to be primarily due to patients with evidence of previous 88 
urinary tract infections 89 
 Co-amoxiclav-resistant bloodstream infections rose significantly faster than co-90 
amoxiclav-susceptible bloodstream infections, with the greatest number of co-91 
amoxiclav-resistant bloodstream infections in 2016 being in patients discharged more 92 
than a month previously (i.e. community-associated) 93 
 Higher co-amoxiclav use in primary care in the previous year was associated with 94 
higher rates of co-amoxiclav-resistant E. coli urinary tract infections in the 95 
subsequent year, supporting drives to reduce broad-spectrum and inappropriate 96 
antibiotic use in primary care 97 
6 
 Despite substantial increases in co-amoxiclav-resistant bloodstream infections there 98 
was no evidence that mortality was increasing in these cases; this does not support 99 
moving to broader empiric antibiotic prescribing in hospitals (i.e. carbapenems, 100 
piperacillin-tazobactam) 101 
Implications of all available advice 102 
This suggests that government strategies to effectively reduce E. coli bloodstream infections 103 
should prioritise community settings rather than focus primarily on healthcare-associated 104 
settings. The absence of an increased mortality signal suggests that co-amoxiclav resistant 105 
E. coli infections are either being successfully treated by dual empiric therapy in severe 106 
cases (e.g. with concomitant gentamicin), can be “rescued” once isolate susceptibilities 107 
become available, or currently deployed phenotypic susceptibility testing breakpoints do not 108 
adequately correlate with clinical outcome. Crucially, none of these explanations support 109 
broadening empiric antibiotic prescribing from co-amoxiclav. 110 
  111 
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Introduction  112 
Escherichia coli is a major cause of bloodstream infection (BSI)1 and a critical antimicrobial 113 
resistance (AMR) concern;2 rates are rising across Europe.3–5 E. coli bloodstream infections 114 
(EC-BSIs) reported (voluntarily) to Public Health England rose by 44% between 2003-2011.6  115 
After introducing mandatory reporting in July 2011, a further 28% increase occurred by July-116 
September 2016, to 78·8 cases/100,000 population.7  117 
 118 
As elsewhere, most (>70%) EC-BSIs in England are identified within two days of admission.7 119 
However, the impact of previous hospital-exposure on trends in EC-BSI has not been 120 
comprehensively investigated, with only two relevant previous studies, one in the Calgary 121 
Health Region 2000-2006,8 and another in Oxfordshire in 1999-20119; further, the relevance 122 
of such older studies to current trends is unclear. EC-BSI source may also differ by hospital-123 
exposure. In a recent study, ~50% of EC-BSIs in England were considered most likely due 124 
to urinary tract infections (UTIs);10 gastrointestinal foci are more common in inpatients.7 125 
 126 
30-day all-cause mortality following EC-BSI is ~16%;11 and could rise given the impact of 127 
increasing AMR on outcomes.2 In Oxfordshire, EC-BSI incidence rises through 2011 were 128 
essentially confined to ciprofloxacin-, co-amoxiclav-, cefotaxime- and/or aminoglycoside-129 
resistant organisms.9 The reasons for rising resistant EC-BSI, and EC-BSI more generally, 130 
are unclear, with increased antibiotic usage or resistance implicated in some, but not all, 131 
studies;5,12–18 an aging population is also hypothesised to contribute.5 Although individual 132 
hospital and primary-care guidelines vary, in England co-amoxiclav is commonly used as 133 
empiric treatment, particularly for community-acquired pneumonia and undifferentiated 134 
sepsis in hospitals,19 as well as for prophylaxis, making it one of the most commonly used 135 
antibiotics in England.20 Hence, trends in co-amoxiclav resistance are particularly important.  136 
We therefore aimed to investigate possible drivers of changes in EC-BSI incidence and 137 
antibiotic susceptibilities in Oxfordshire over the last two decades, while stratifying for 138 
hospital-exposure. We hypothesized that increases may be due to features of the at-risk 139 
8 
population (therefore exploring demographics, recurrent infections, increased 140 
ascertainment), healthcare-history (previous urine cultures, catheter specimens, admission 141 
diagnoses, antibiotic usage), and/or the bacteria (exploring mortality/severity, AMR burden). 142 
   143 
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Methods 144 
The Infections in Oxfordshire Research Database (IORD)21 records all admissions to the 145 
Oxford University Hospitals National Health Service Foundation Trust (OUH), Oxfordshire, 146 
UK, from April 1997, linked by patient with microbiology and biochemistry/haematology 147 
results. The four OUH hospitals provide all acute care, microbiology and pathology services 148 
in the region (~680,000 individuals). Out-of-hospital mortality was determined by updates 149 
from a national information system. IORD has Research Ethics Committee and 150 
Confidentiality Advisory Group approvals (14/SC/1069, ECC5-017(A)/2009). Data on 151 
antibiotic prescribing and numbers of registered patients for each primary-care facility were 152 
obtained from the Health and Social Care Information Centre (available January 2011-153 
December 2016 only).  154 
 155 
The primary study outcome was EC-BSI, defined as E. coli isolated from blood cultures 156 
taken 01/Jan/1998-31/Dec/2016 inclusive, including polymicrobial cultures (13%), without 157 
age restriction and de-duplicated within 14-days of each index positive following mandatory 158 
reporting guidelines.22 For context we also analysed E. coli UTIs (EC-UTIs), defined as pure 159 
culture from urine of >104 colony-forming-units/ml, de-duplicated within 90-days to avoid 160 
over-counting ongoing infections.23 We classified EC-BSIs/EC-UTIs as ‘nosocomial’ if 161 
samples were taken >48h post-admission until discharge.24 All other EC-BSIs/EC-UTIs were 162 
classified as ‘community’, ‘quasi-community’ or ‘quasi-nosocomial’ if the last hospital 163 
discharge was >1 year, 31-365 days, or 0-30 days previously.8,25–27 We also calculated 164 
incidences of first ever and recurrent EC-BSIs. See Supplementary Methods for further 165 
details. 166 
 167 
To assess demographic changes such as ageing and population growth, we standardised 168 
incidence against the 1998 Oxfordshire age-sex population (estimates from the UK Office for 169 
National Statistics).28 To assess ascertainment, we considered the incidence of blood/urine 170 
10 
cultures, regardless of result, and also additionally standardised outcome for culture rates. 171 
Both standardisations were done using inverse probability weighting. 172 
 173 
As a proxy for changes in bacterial virulence, we considered separately 30-day mortality 174 
after sample collection, and levels of monocytes, neutrophils, lymphocytes, C-reactive 175 
protein (CRP), creatinine and urea at sample collection (closest value within [-2,+2] days). 176 
To assess the impact of AMR, which might also affect treatment outcomes, we investigated 177 
EC-BSI reported by the diagnostic laboratory as resistant to amoxicillin, co-amoxiclav, 178 
trimethoprim, gentamicin, ciprofloxacin, ceftriaxone, ceftazidime, piperacillin-tazobactam and 179 
meropenem, and EC-UTI reported as resistant to amoxicillin, co-amoxiclav, trimethoprim, 180 
ciprofloxacin, nitrofurantoin and cefalexin (the only drugs consistently tested throughout the 181 
study period). Susceptibility testing was performed using disk-diffusion to 31/Jan/2013, then 182 
by microbroth dilution (BD Phoenix™ Automated Microbiology System, Beckton Dickinson, 183 
Franklin Lakes, NJ, USA) (see Supplementary Methods). 184 
 185 
Guidelines recommend empirical treatment for uncomplicated UTIs and for urine samples to 186 
be sent for microbiological testing only from individuals with clinical treatment failure, 187 
frequent or recurrent UTI or with possibly resistant infections.20 To investigate this group, we 188 
first classified EC-BSIs by whether the patient had ever had an EC-UTI ≥3 days previously. 189 
To investigate the contribution of UTI around EC-BSIs, including symptomatic UTIs where E. 190 
coli was not isolated, we classified EC-BSIs as ‘likely urine-associated’ (urine sample taken 191 
3-30 days previously; EC-UTI or mixed growth/negative but UTI suspected clinically from 192 
request codes), ‘urosepsis’ (defined as ‘likely urine-associated’ but urine samples within (-193 
3,+2] days of the EC-BSI), ‘unlikely urine-associated’ (UTI with non-E. coli pathogen or no 194 
urine sample), or ‘unknown’ (other) (details in Supplementary Methods). To investigate the 195 
contribution of catheters, we classified EC-BSIs by whether a catheter urine specimen had 196 
been submitted up to and including the day of blood collection (regardless of result).  197 
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 198 
To investigate the contribution of previous admission characteristics, we classified quasi-199 
nosocomial EC-BSIs by whether the primary diagnostic code of the antecedent admission 200 
was infection-related, or any diagnostic code (primary/secondary) included UTI 201 
(Supplementary Methods and Results).  202 
 203 
Statistical analysis 204 
Counts of EC-BSI/EC-UTI per month were modelled using negative-binomial regression 205 
(incorporating overdispersion), assuming the same underlying population (no offset). 30-day 206 
mortality following EC-BSI and CRP≥156mg/L at EC-BSI (binary) were modelled using 207 
poisson regression (to estimate analogous rate ratios), and absolute values of other test 208 
results were modelled using median quantile regression, both against sample date and 209 
adjusted for age and sex. Changes in trends in all outcomes were estimated using iterative 210 
sequential regression,29 and compared between outcomes using stacked regression.30 211 
Bivariate cross-correlations summarised univariable associations between hospital 212 
antimicrobial usage and nosocomial co-amoxiclav-resistant EC-BSIs. To estimate 213 
associations with primary care co-amoxiclav usage, co-amoxiclav defined-daily-doses 214 
(DDDs) per 1000 registered patients in the previous or current year and primary-care facility 215 
were included as explanatory variables with the number of patients per primary-care facility 216 
per year as an offset in negative-binomial regression models for yearly co-amoxiclav 217 
resistant EC-UTIs, EC-UTIs and all urines regardless of result. Full details, including missing 218 
data, are provided in Supplementary Methods.  219 
 220 
Analyses were conducted using R 3.2.2,31 and STATA 14.1 for stacked regression and 221 
probability weighted analyses. 222 
 223 
Role of the funding source 224 
12 
The study sponsor had no role in design, data collection, analysis, interpretation, or writing of 225 
the report. The corresponding author had full access to all the data and had final 226 
responsibility for the decision to submit for publication. 227 
  228 
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Results  229 
After 14-day de-duplication, from 1998-2016 5706 EC-BSIs occurred in 5215 patients (i.e. 230 
9% recurrences (relapse and/or reinfection)). Recurrences occurred a median(IQR) 144(39-231 
577) days apart: of 391 patients with recurrences, 324(83%) had one and 52(13%) had two 232 
(range 1-8). Overall incidence increased year-on-year (annual incidence rate ratio 233 
(IRR)=1·06 (95% CI 1·05-1·06)). Most (5393(95%)) EC-BSI cases were admitted to OUH 234 
before or within 24h following blood culture (remainder mostly sampled in emergency 235 
departments/community hospitals). Only 1365(24%) EC-BSIs were ‘nosocomial’ (≥48h post-236 
admission). A further 1132(20%) were ‘quasi-nosocomial’ (discharged up to 30 days 237 
previously), 1346(24%) were ‘quasi-community’ (discharged 31-365 days previously) and 238 
1863(33%) were ‘community’ cases (discharged >1 year previously or never previously 239 
admitted to OUH). The 1132 quasi-nosocomial EC-BSI were most commonly previously 240 
admitted for malignancy (395,35%), gastrointestinal disorders (177,16%), and 241 
renal/urological disorders (164,14%) (Supplementary Table 1), with no major temporal 242 
variability (Supplementary Figure 1A). 243 
 244 
Incidence trends for EC-BSIs varied substantially with hospital-exposure (Figures 1A&2A, 245 
Supplementary Table 2), with overall increases clearly driven by community and quasi-246 
community hospital-exposure groups, and no evidence of different incidence trends between 247 
these two groups in 2016 (pheterogeneity=0·27). By contrast, quasi-nosocomial and nosocomial 248 
EC-BSIs increased more slowly. Considering only the first EC-BSI per patient or subsequent 249 
EC-BSIs (Figure 2A, Supplementary Figure 2) gave broadly similar results. Year-on-year 250 
increases in the incidence of first EC-BSI became smaller (but still significant) the more 251 
recent the hospital exposure. Quasi-community recurrent EC-BSI increased faster than first 252 
EC-BSIs (pheterogeneity<0·0001) and the stable current trend in the incidence of all quasi-253 
nosocomial EC-BSIs was driven by reduced recurrences in this group. 254 
 255 
14 
After 90-day de-duplication, 228376 EC-UTIs occurred in 137075 patients (i.e. 40% 256 
recurrences (relapse/re-infection)). Recurrences occurred a median(IQR) 457(200-1119) 257 
days apart: of the 41371(30%) patients with recurrences, 22011(53%) had one and 258 
8742(21%) had two (range 1-33). 12898(9%) patients had two EC-UTI within six months. 259 
EC-UTIs were predominantly community (160359,70%), and less commonly quasi-260 
community (44283,19%), quasi-nosocomial (12764,6%) or nosocomial (10970,5%). 261 
Incidence of EC-UTI increased over 1998-2016 in community, quasi-community and quasi-262 
nosocomial groups, although current trends were fairly stable, but declined significantly in 263 
the nosocomial group (Figure 1B&2B). Furthermore, increases were accounted for entirely 264 
by substantial increases in recurrent EC-UTI episodes, with decreasing overall trends in first 265 
EC-UTI per patient (Supplementary Figure 3).  266 
 267 
In 2016, therefore, recurrences accounted for at least half of community, quasi-community 268 
and quasi-nosocomial EC-UTIs, and around a fifth of quasi-community and quasi-269 
nosocomial EC-BSIs (Supplementary Table 3). 270 
 271 
Impact of population and sampling on EC-BSI  272 
Blood culture submission rates increased substantially from 1998-2016 for community/quasi-273 
community/quasi-nosocomial groups (Figure 2A, Supplementary Figure 4), raising the 274 
possibility that observed increases in EC-BSIs were driven by increases in the use of blood 275 
cultures as a diagnostic test. However, there was no suggestion that the indications for blood 276 
culture changed with time: changes in neutrophils and CRP when cultures were taken were 277 
small and not clinically meaningful and 30-day mortality post blood culture sampling was 278 
stable (Supplementary Figure 5). Further, increases in community blood culture 279 
submission rates were significantly smaller than increases in community EC-BSIs 280 
(p=0·0006, Figure 2A). Standardising for age and sex explained only 10-26%, and 281 
standardising additionally for blood cultures taken only 9-28%, of the increase in overall or 282 
first-per-patient EC-BSIs, with the greatest percentage explained in nosocomial EC-BSIs and 283 
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the least in community EC-BSIs (Supplementary Tables 4,5). In contrast, urine sample 284 
submission was more stable over time (Supplementary Figure 6).  285 
 286 
Disease severity of EC-BSIs 287 
30-day mortality following EC-BSI declined slightly in the nosocomial (IRR=0·98 (95% CI 288 
0·96,1·00), p=0·03) and quasi-nosocomial (IRR=0·98 (0·95,1·00), p=0·06) groups, but there 289 
was no evidence for changes in quasi-community (IRR=0·99 (0·96,1·01), p=0·32) and 290 
community (IRR=0·99 (0·96,1·01), p=0·21) groups (Supplementary Figure 7, adjusting for 291 
age and sex). Mortality was substantial at 25% (340/1363), 19% (217/1128), 16% 292 
(219/1344) and 14% (254/1784) across the groups, respectively (Supplementary Table 6). 293 
Changes in haematology/biochemistry test results over time were small and/or non-294 
significant (Supplementary Figure 7), and did not indicate that less severe infections were 295 
being identified, or that there were changes in pathogen virulence.  296 
 297 
Impact of previous illness on EC-BSI 298 
1755(31%) EC-BSI occurred in patients with an EC-UTI ≥3 days previously (median(IQR) 299 
213(43-918) days previously). However, incidence trends were broadly similar for EC-BSIs 300 
with or without EC-UTIs ≥3 days previously, although quasi-community EC-BSIs were rising 301 
particularly fast in those with previous EC-UTIs (pheterogeneity<0·0001, Figure 2A, 302 
Supplementary Figure 8). We next explored whether EC-BSI increases were associated 303 
with past symptomatic UTIs, including those without positive urine cultures. Considering 304 
urine samples/results taken within 30 days before the EC-BSI, and incorporating information 305 
on mixed growth and request codes, only 760(13%) EC-BSIs were ‘likely urine-associated’, 306 
with 1613(28%) ‘urosepsis’, 1613(28%) ‘unlikely urine-associated’ (of which 181[11%] had a 307 
contemporaneous urine specimen positive for another pathogen), and 1720(30%) unknown. 308 
However, the relative proportions of these did not vary substantially over time (Figure 3), 309 
suggesting no specific subgroup was associated with incidence increases. Percentages of 310 
EC-BSIs with a previous catheter urine specimen (CSU) increased across hospital-exposure 311 
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groups, being present in 365(20%) community, 364(32%) quasi-community, 541(40%), 312 
quasi-nosocomial, 584(43%) nosocomial cases. However, incidence trends were broadly 313 
similar for EC-BSIs with or without a previous CSU (Figure 2A, Supplementary Figure 9), 314 
although quasi-nosocomial EC-BSIs were rising particularly fast in those with previous CSUs 315 
(pheterogeneity=0·0002), while increases in nosocomial EC-BSIs were restricted to those without 316 
previous CSUs (pheterogeneity=0·03).  317 
 318 
Antimicrobial susceptibility 319 
Exploring the possibility that EC-BSI increases were associated with AMR, the only EC-BSI 320 
antibiotic-resistant phenotype that consistently increased across all hospital-exposure 321 
groups was co-amoxiclav (p<0·0001; Figures 2A&4), with 212(41%) of 515 EC-BSIs in 322 
2016 being co-amoxiclav resistant (Supplementary Tables 6,7). Co-amoxiclav-resistant 323 
EC-BSIs increased significantly faster than co-amoxiclav-susceptible EC-BSIs 324 
(pheterogeneity<0·0001), but community and quasi-community co-amoxiclav-susceptible EC-325 
BSIs were still increasing significantly in 2016 (p<0·0001) (Figure 4). Most (942/1412, 67%) 326 
co-amoxiclav-resistant EC-BSIs remained susceptible to gentamicin and ciprofloxacin 327 
(Figure 4).  328 
 329 
Increases in other antibiotic-resistant EC-BSIs were most notable in the community and 330 
quasi-community groups, with significant year-on-year increments in all but trimethoprim-331 
resistant EC-BSIs, which remained stable in these groups (Supplementary Figure 10). Co-332 
amoxiclav-resistant EC-UTIs also rose consistently and significantly regardless of 333 
healthcare-exposure, but trends were more variable for other antibiotics (Supplementary 334 
Figure 11). In 2016, 3921/13792(28%) EC-UTIs were co-amoxiclav-resistant. 335 
 336 
Given the substantial increase in co-amoxiclav resistant EC-BSIs, we investigated whether 337 
severity differed in susceptible versus resistant cases. There was no strong evidence that 338 
co-amoxiclav-resistant EC-BSIs were associated with higher neutrophil counts in any 339 
17 
hospital-exposure group (p>0·04, adjusting for age and sex), or that neutrophil counts were 340 
changing differently over time in co-amoxiclav-resistant versus co-amoxiclav-susceptible EC-341 
BSI (pheterogeneity>0·67; Supplementary Figure 12). Mortality was higher for co-amoxiclav-342 
resistant vs co-amoxiclav-susceptible nosocomial EC-BSIs (unadjusted 30% (117/395) vs 343 
23% (222/967) respectively; rate ratio adjusting for age and sex =1.32 (1.13-1.46) p=0·002). 344 
However, there was no evidence of higher mortality in co-amoxiclav-resistant 345 
community/quasi-community/quasi-nosocomial EC-BSIs (p>0·48), and mortality did not 346 
change differently over time in any group (pheterogeneity>0·35; Supplementary Figure 12, 347 
Figure 2C) (Supplementary Table 6).  348 
 349 
The strongest associations with nosocomial co-amoxiclav-resistant EC-BSIs were with 350 
hospital co-amoxiclav (cross-correlation 0·75) and third-generation cephalosporin (0·80) use 351 
(Supplementary Table 8; available only financial years 2003-2014). Community prescribing 352 
data was only available from 2011, and co-amoxiclav-resistant EC-BSIs were too few to 353 
consider relationships with co-amoxiclav use. However, from 2012-2016, primary care 354 
facilities prescribing more co-amoxiclav in the previous year had higher rates of subsequent 355 
co-amoxiclav-resistant-community-EC-UTIs (IRR (per 100DDD higher)=1·05 (95% CI 1·02-356 
1·08) p=0·003, Figure 5), co-amoxiclav use in the current year did not add any predictive 357 
value (p=0.12 adjusted for previous year vs p=0.64 alone). In contrast, facilities prescribing 358 
more co-amoxiclav in the current year had higher rates of community-EC-UTIs and urine 359 
specimen submission (IRR=1·02 (1·00-1·04) p=0·01 and 1.02 (1·01-1·03) p=0·0001 360 
respectively); co-amoxiclav use in the previous year did not add any predictive value (p=0.58 361 
adjusted for current year vs p=0.11 alone, respectively p=0.21 adjusted for current year vs 362 
p=0.006 alone).. Results were seen across all samples regardless of hospital-exposure 363 
group (Supplementary Figure 13), and also when adjusting instead for the proportion aged 364 
over 65 and male in 2017 per practice. There was no association between current/prior 365 
quinolone use and any of these outcomes (p>0.9).  366 
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Discussion 367 
We have explored potential explanations for continuing increases in EC-BSI in Oxfordshire 368 
over 19 years using extensive, routinely-collected data, including laboratory/microbiology 369 
results. Incidence varied dramatically by hospital-exposure, with increases being driven by 370 
community/quasi-community cases. This is important given the National Health Service 371 
ambition to reduce Gram-negative BSIs by targeting ‘healthcare-associated’ cases (although 372 
this definition incorporates recent community antibiotic use). Previous successful campaigns 373 
to reduce methicillin-resistant Staphylococcus aureus (MRSA) BSI and Clostridium difficile 374 
infections also focussed on nosocomial risk factors. Our data suggest that defining 375 
appropriate strategies aiming to reduce community/quasi-community associated EC-BSIs, 376 
such as improved catheter care and improved quality of antibiotic use for UTI management 377 
in the community, might have a greater impact. Given that recent antibiotic use is the 378 
greatest risk factor for subsequent resistant UTIs,32 many people prescribed antibiotics may 379 
not have bacterial UTIs,33 and many bacterial UTIs may resolve in a similar timeframe 380 
without antibiotics,34 better point-of-care tests that predict benefit from antibiotics are 381 
urgently needed to guide prescribing decisions. Co-amoxiclav-resistant EC-BSIs rose 382 
significantly faster than co-amoxiclav-susceptible EC-BSIs, regardless of hospital-exposure, 383 
with the greatest number of co-amoxiclav-resistant EC-BSIs in 2016 being community/quasi-384 
community EC-BSIs. Primary-care facilities with higher co-amoxiclav prescribing rates in the 385 
previous year had more co-amoxiclav resistant EC-UTIs in the subsequent year. Co-386 
amoxiclav is one of the most commonly prescribed antibiotics nationally in both the 387 
community and hospitals in England,20,35 and our findings are consistent with this exerting 388 
selection pressure for co-amoxiclav resistant EC-UTI and EC-BSI. Despite co-amoxiclav 389 
being used for empiric BSI treatment, there were no clinically important changes in mortality.  390 
 391 
EC-BSI is generally considered ‘community-acquired’ although there are differing definitions 392 
of healthcare-associated BSI.7,26 By linking to previous hospital admissions, one major study 393 
strength is that we could identify that incidence trends for non-nosocomial EC-BSIs varied 394 
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significantly by time since discharge. Blood sample submission also increased significantly 395 
over time, potentially increasing ascertainment of ‘mild’ cases. However, blood cultures are 396 
key to the assessment of unwell patients whenever infection is suspected, and there were no 397 
clinically important changes in EC-BSI-associated severity at presentation or mortality, 398 
despite substantially increasing incidence, suggesting major ascertainment bias is unlikely. 399 
As standardising for age/sex using crude data available had at most modest effects, main 400 
analyses did not use this.   401 
 402 
The increasing trend in nosocomial EC-BSI was significantly smaller than for 403 
community/quasi-community EC-BSI in Oxfordshire, as observed nationally.10 Multiple 404 
infection control interventions were rolled out in UK hospitals from 2005-201036,37 in 405 
response to MRSA/C. difficile, and horizontal components could have contributed to lowering 406 
nosocomial rates. Consistent with this, increases in hospital-onset Gram-negative BSI 407 
reversed after introducing a MRSA Prevention Initiative in the US, while community-acquired 408 
incidence remained unchanged.38  409 
 410 
Whereas MRSA and C. difficile are predominantly hospital-associated pathogens, 411 
differences in EC-BSI epidemiology highlight the need for different interventions, particularly 412 
in primary care.7 In particular, recurrences explain relatively little of the ongoing increases in 413 
EC-BSIs, and both co-amoxiclav-resistant and co-amoxiclav-susceptible EC-BSI are rising. 414 
Overall, 42% of EC-BSI appeared to be more likely amenable to urinary-focussed 415 
intervention, similar to an England-wide study that found 51% of EC-BSIs had an underlying 416 
urogenital tract focus, with UTI treatment in the prior four weeks the largest independent risk 417 
factor.10 In our study, 13% of EC-BSIs were likely urine-associated and 28% presented as 418 
urosepsis; the first group may be most tractable for prevention but was smallest in both 419 
community and quasi-community EC-BSI, whereas urosepsis was the largest. One key 420 
limitation is lack of data on visits to primary-care facilities, meaning our assessment of 421 
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urinary sources relied on samples being submitted for microbiological testing, and may 422 
therefore underestimate the true burden of urinary-associated EC-BSI, since some patients 423 
may have had UTI symptoms and either did not present to primary-care facilities or were 424 
treated empirically without a urine sample being submitted. Changes in patient health-425 
seeking behaviour or sample submission over time could lead to bias in attributing EC-BSIs 426 
to different sources. However, successfully treated UTIs, and those resolving without 427 
intervention, should not cause bacteraemia, and bacteraemias due to UTI treatment failure 428 
should be ascertained within our data since guidelines recommend urine samples be 429 
submitted from individuals with clinical treatment failure, frequent or recurrent UTI or with a 430 
possibly resistant infection.20 . Much of the burden of EC-BSIs, and especially the 431 
rising incidence, is hypothesized to arise from poor urinary catheter care. However, only 432 
20% and 30% of the community and quasi-community groups, where incidence is increasing 433 
fastest, had a previous CSU, and there was no evidence that incidence was increasing 434 
faster in those with a previous CSU versus without. One key limitation is that we did not have 435 
records of the presence of a catheter, but only urine specimens recorded as being taken 436 
from a catheter, arguing that if a catheter was present and causing infection, a specimen 437 
would likely have been taken from it at some time. Similarly, we did not have direct 438 
information on the source of each individual EC-BSI. Interestingly, there was strong 439 
evidence that quasi-nosocomial EC-BSIs with UTI or infectious diagnostic codes in the 440 
previous admission were rising faster than those without (Supplementary Figure 1). This 441 
may reflect underlying predisposition to infection (e.g. chronic illnesses), or that prior 442 
antibiotic use adversely affects a patient’s microbiota potentially leading to 443 
colonisation/overgrowth by more pathogenic E. coli, thus predisposing to EC-BSI. 444 
 445 
A limitation of surveillance studies is changes in antimicrobial susceptibility testing 446 
methodology (here in February 2013). Whilst testing protocol can affect results,39,40 crucially 447 
changes in co-amoxiclav resistance around this time occurred regardless of method 448 
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(Supplementary Figure 14). Recent data suggest that broth dilution (BD-Phoenix) and the 449 
gold standard agar dilution have high agreement;41 thus, rising rates of co-amoxiclav-450 
resistant (as defined by EUCAST breakpoints) EC-BSI/EC-UTI are likely correct.  451 
 452 
We also found that primary-care facilities with higher co-amoxiclav prescribing rates in the 453 
previous year were more likely to have patients diagnosed with co-amoxiclav resistant EC-454 
UTIs in the subsequent year. Similar associations between trimethoprim use and 455 
trimethoprim-resistant urine-associated EC-BSI have been reported in adult women in 456 
England,16 and recently more generally across multiple antibiotic classes for EC-UTI.17 Over 457 
the period with contemporary prescribing data, co-amoxiclav-resistant EC-BSI were too few 458 
to investigate associations with antibiotic prescribing within the community. Assessing 459 
usage-resistance associations is complicated, since changes in use of one antibiotic are 460 
generally accompanied by compensatory prescribing, and may be compounded by multi-461 
drug resistance. Comparisons are ecological, which is a key limitation. Our results may also 462 
not be generalizable; for example, although the region we studied is sizeable (~1% of the 463 
UK), we did not observe a uniform decrease in cephalosporin-resistant and quinolone-464 
resistant EC-BSIs as seen in BSI caused by Enterobacteriaceae.15 Such differences likely 465 
reflect a complex interplay of selection pressures. 466 
 467 
A key limitation is that we were unable to assess associations between individual-patient 468 
antibiotic use (not available in the research database) and risk of resistant infections or 469 
between specific empiric regimens and outcome; these are important future research 470 
priorities. However, there were no clinically important changes in mortality overall, by co-471 
amoxiclav-susceptible/resistant phenotype, or by hospital-exposure. Co-amoxiclav remains 472 
our recommended first-line empiric treatment for most severe infections, so the substantial 473 
increase in incidence of co-amoxiclav-resistant bacteraemias suggests either that initial 474 
inappropriate treatment can be successfully rescued,42 or that the current definition of co-475 
amoxiclav breakpoints may be suboptimal.43 Crucially, neither scenario supports a move 476 
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towards broader empiric antibiotic treatment, consistent with prevailing antimicrobial 477 
stewardship messages.  478 
 479 
Another inherent limitation is restriction to the routinely collected data available, in particular 480 
lack of information on prognostic factors such as illness severity scores, lack of individual 481 
antibiotic prescribing data (as above), and having only antibiograms since strain typing was 482 
not routinely performed. Representative isolates from 2008-present have been selected for 483 
whole genome sequencing and their analysis may increase our understanding of the 484 
pathogenesis of EC-BSI. For example, the distinct change in the monthly incidence of 485 
community EC-BSI in July 2010 could reflect the introduction and proliferation of a new 486 
strain of E. coli to the region.44  487 
 488 
In summary, on-going increases in EC-BSI were driven by community and quasi-community 489 
cases, and cannot be attributed only to increased recurrences or an aging population. 490 
Absence of changes in mortality and severity do not support ascertainment bias playing a 491 
major role, although this cannot be excluded. Whilst urinary foci are clearly important, at 492 
present the scope for intervening to prevent UTIs progressing to bacteraemia could be 493 
limited. Notably, higher co-amoxiclav use in primary care was associated with higher 494 
subsequent rates of co-amoxiclav-resistant EC-UTI, supporting drives to reduce broad-495 
spectrum and inappropriate antibiotic use. However, despite substantial increases in co-496 
amoxiclav-resistant EC-BSI, evidence that patient clinical outcomes are no worse does not 497 
support broadening empiric antibiotic prescribing from co-amoxiclav.11 498 
 499 
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Figure legends 680 
Figure 1. Monthly (A) EC-BSI and (B) EC-UTI according to recent hospital-exposure (first 681 
and recurrent infections).  682 
Footnote: only counting EC-BSI recurrences occurring >14 days after an index positive, and 683 
EC-UTI recurrences occurring >90 days after an index positive. Thick blue line represents 684 
the estimated incidence by iterative sequential regression (ISR). Blue lines at the base of the 685 
graph represent 95% CI around the breakpoints estimated by the ISR model. IRR=annual 686 
incidence rate ratio in 2016, that is the relative increase in rate per year as estimated in 687 
2016. 688 
 689 
Figure 2. Summary of incidence trends in 2016 for (A) EC-BSIs, (B) EC-UTIs, and (C) 690 
severity of co-amoxiclav resistant and sensitive EC-BSIs. 691 
Footnote: IRR=annual incidence rate ratio in 2016, that is the relative increase in rate per 692 
year as estimated in 2016. See Supplementary Table 1 for numbers and heterogeneity tests. 693 
 694 
Figure 3. Annual EC-BSI according to recent hospital-exposure and urine sample 695 
submission/results. 696 
Footnote: See Supplementary Methods for definitions. 697 
 698 
Figure 4. Annual EC-BSI susceptible and resistant to co-amoxiclav, with and without 699 
resistance to gentamicin and ciprofloxacin, according to recent hospital-exposure. 700 
Footnote: IRR=annual incidence rate ratio in 2016, that is the relative increase in rate per 701 
year as estimated in 2016. 702 
 703 
Figure 5. Community co-amoxiclav-resistant EC-UTIs (A), community EC-UTIs (B) and 704 
community urine samples submitted regardless of result (C) per 1000 patients per primary-705 
care facility 2012-2016 compared with co-amoxiclav usage. 706 
29 
Footnote: showing one record per year per primary-care facility. For (A) the strongest 707 
predictor was co-amoxiclav DDD per 1000 patients per general practice in the previous year; 708 
for (B) and (C) the strongest predictor was co-amoxiclav DDD per 1000 patients per general 709 
practice in the current year. Spearman rho (and models) for each panel excludes 5 facilities 710 
which submitted less than 151 samples over 2011-2016 (all others submitted over 300). 711 
Spearman rho for univariable associations with previous vs current co-amoxiclav usage for 712 
the 3 outcomes left to right =0.20 vs =0.04, =0.33 vs =0.35, =0.37 vs =0.40 713 
respectively. 714 
